NASDAQ:CATB - Catabasis Pharmaceuticals, Inc.
$8.10
 $-0.10
-1.22%
4:00PM EDT
2019-04-18
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CATB     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 96   203. 85   241. 91  
42 stocks rank:  3. 34 K 1. 44 K 1. 05 K
# analyst opinions:  3. 00   14. 51   13. 97  

quick ratio:  9. 01   5. 27   1. 81  
current ratio:  9. 33   5. 62   2. 25  

target price low:  15. 00   84. 80   115. 21  
target price avg:  11. 35   111. 51   137. 51  
target price high:  7. 20   135. 81   157. 84  
1-yr high:  17. 90   114. 23   138. 78  
last close:  8. 10   87. 66   116. 69  
50-day avg:  6. 43   95. 54   123. 44  
200-day avg:  6. 60   94. 25   121. 11  
1-yr low:  0. 41   72. 78   98. 34  
volume:  145. 18 K 4. 11 M 8. 07 M
50-day avg volume:  237. 03 K 2. 76 M 5. 02 M
200-day avg volume:  585. 42 K 2. 92 M 4. 59 M

1-day return:  -1. 22 % -0. 41 % 0. 07 %
this week return:  -10. 10 % -5. 74 % -4. 11 %
12-wk return:  31. 07 % 1. 61 % -0. 05 %
52-wk return:  -50. 30 % 3. 12 % 8. 78 %

enterprise value (EV):  55. 55 M 48. 94 B 114. 64 B
market cap:  93. 12 M 43. 07 B 104. 73 B
EBITDA:  -25. 35 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -2. 19   4. 22   12. 73  
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -25. 87 M 2. 20 B 4. 20 B

shares outstanding:  11. 50 M 571. 70 M 1. 24 B
shares:  10. 12 M 571. 81 M 1. 23 B
shares short:  575. 90 K 10. 17 M 13. 00 M
shares short prior month:  456. 26 K 9. 54 M 17. 33 M
short ratio:  2. 14   5. 41   3. 28  
short % of float:  10. 36 % 5. 45 % 2. 38 %
total cash/share:  3. 27   11. 14   9. 33  
total cash:  37. 57 M 6. 71 B 7. 15 B
free cash flow:  -13. 71 M 3. 58 B 2. 96 B
operating cash flow:  -23. 46 M 4. 15 B 4. 30 B

book value:  4. 89   12. 78   26. 92  
price/book:  1. 66   3. 06   -1. 74  
operating margins:  0. 00 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  -89. 80 % --- ---
1-yr mean volatility:  -0. 57 % 0. 03 % 0. 04 %

1-yr EPS:  -5. 12   2. 40   4. 10  
forward EPS:  -2. 35   3. 97   7. 13  
P/E:  -1. 58   13. 63   22. 72  
forward P/E:  -3. 45   -15. 95   13. 99  
PE/G:  0. 04   -1. 65   -1. 32  
growth:  -35. 75 % 127. 12 % 29. 61 %
earnings high:  -0. 53   1. 00   1. 66  
earnings avg:  -0. 69   0. 77   1. 53  
earnings low:  -0. 88   0. 50   1. 39  
revenue high:  -0. 00   2. 68 B 10. 78 B
revenue avg:  -0. 00   2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -55. 79 % -2. 75 % 4. 55 %
return on equity:  -110. 71 % -18. 45 % 5. 46 %

beta (1yr vs S&P500):  1. 11   1. 25   0. 93  
sharpe (1yr):  -1. 25   0. 37   0. 70  

held % insiders:  1. 87 % 6. 39 % 3. 38 %
held % institutions:  33. 18 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : CATB
.        + 0 =             0 :: INITIAL WEIGHT
.   + 72.762 =        72.762 :: inverse volume-to-price addition
.   + 37.575 =       110.337 :: spline projection addition
.    x 6.744 =       744.066 :: 13 weeks' performance factor
.    x 0.673 =       500.769 :: one-year gains+dividend factor
.    x 1.431 =       716.812 :: industry recommendation factor
.    x 0.994 =       712.813 :: return on assets factor
.    x 0.989 =       704.921 :: return on equity factor
.    x 2.341 =      1650.298 :: current ratio factor
.    x 1.061 =       1750.32 :: quick ratio factor
.    x 1.211 =      2120.193 :: short ratio factor
.    x 2.017 =      4275.492 :: price-to-book factor
.    x 1.277 =      5458.525 :: 5-day avg > 200-day avg
.    x 1.312 =      7159.333 :: 5-day avg > 50-day avg
.     x 2.15 =     15394.935 :: P/E weight
.     x 2.18 =      33562.74 :: PE/G factor
.     x 1.74 =     58396.687 :: beta factor
.    x 0.638 =     37260.281 :: sharpe factor
.    x 2.022 =     75348.633 :: target low factor
.    x 1.211 =     91268.078 :: target mean factor
.    x 0.967 =     88225.808 :: target high factor
.     x 1.31 =    115565.919 :: industry 2-weeks return factor
.    x 0.905 =    104597.243 :: "drift" penalty 2 days ago
.    x 0.996 =     104204.19 :: overall "drift" factor
.    x 0.996 =    103795.564 :: largest single-day jump factor
.     x 0.11 =      11431.23 :: low price factor
.      x 1.0 =     11429.374 :: factor hist industry gain for week 16
.   cubeRoot =        22.525 :: reduced to standardize
.    - 25.85 =         0.957 :: add/subtract for performance
.                      0.957 :: FINAL WEIGHT for NASDAQ:CATB


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org